● Recruiting

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Condition: PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · NSCLC · Sponsor: Tango Therapeutics, Inc.

PhasePhase 1/Phase 2

Planned participants183

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.

This description comes directly from the study's public registry record.

Talk to the study team

Maxim Pimpkin, MD, PhD · 857-320-4899 · clinicaltrials@tangotx.com

Always discuss trial participation with your own doctor first.

Locations (18)

Mayo Clinic Scottsdale	Scottsdale, Arizona, United States	Recruiting
Sarah Cannon Research Institute Denver	Denver, Colorado, United States	Recruiting
Georgetown University Medical Center	Washington D.C., District of Columbia, United States	Recruiting
Mayo Clinic Jacksonville	Jacksonville, Florida, United States	Recruiting
Northwestern Memorial Hospital	Chicago, Illinois, United States	Recruiting
University of Indiana	Indianapolis, Indiana, United States	Recruiting
University of Iowa Health Care	Iowa City, Iowa, United States	Recruiting
Massachusetts General Hospital	Boston, Massachusetts, United States	Recruiting
Dana-Farber Cancer Institute	Boston, Massachusetts, United States	Recruiting
Mayo Clinic Cancer Center	Rochester, Minnesota, United States	Recruiting
Nebraska Cancer Specialists	Omaha, Nebraska, United States	Recruiting
NYU Langone Health	New York, New York, United States	Recruiting

+ 6 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06922591